Based on our prior work [39] and the above results, we reasoned that use of a RARα-selective agonist might circumvent the pro-proliferative and pRb repressive effects induced by activation of RARγ [11] and thereby prevent tumor development. The gene discussed is RARG; the disease is neoplasm.